Nothing Special   »   [go: up one dir, main page]

FR09C0011I2 - - Google Patents

Info

Publication number
FR09C0011I2
FR09C0011I2 FR09C0011C FR09C0011C FR09C0011I2 FR 09C0011 I2 FR09C0011 I2 FR 09C0011I2 FR 09C0011 C FR09C0011 C FR 09C0011C FR 09C0011 C FR09C0011 C FR 09C0011C FR 09C0011 I2 FR09C0011 I2 FR 09C0011I2
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR09C0011C
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26736901&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR09C0011(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of FR09C0011I1 publication Critical patent/FR09C0011I1/fr
Application granted granted Critical
Publication of FR09C0011I2 publication Critical patent/FR09C0011I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/40—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/42—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by saturated carbon chains
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR09C0011C 1997-08-28 2009-03-12 Active FR09C0011I2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6983797P 1997-08-28 1997-08-28
US5780397P 1997-08-28 1997-08-28
PCT/EP1998/005414 WO1999011605A1 (en) 1997-08-28 1998-08-26 Certain 5-alkyl-2-arylaminophenylacetic acids and derivatives

Publications (2)

Publication Number Publication Date
FR09C0011I1 FR09C0011I1 (en) 2009-04-17
FR09C0011I2 true FR09C0011I2 (en) 2011-04-01

Family

ID=26736901

Family Applications (1)

Application Number Title Priority Date Filing Date
FR09C0011C Active FR09C0011I2 (en) 1997-08-28 2009-03-12

Country Status (34)

Country Link
US (5) US6291523B1 (en)
EP (1) EP1007505B1 (en)
JP (1) JP3704470B2 (en)
KR (1) KR100637296B1 (en)
CN (1) CN1140500C (en)
AR (1) AR015157A1 (en)
AT (1) ATE237580T1 (en)
AU (1) AU743371B2 (en)
BR (1) BR9812010B1 (en)
CA (1) CA2298033C (en)
CO (1) CO4960662A1 (en)
CY (1) CY2007020I2 (en)
CZ (1) CZ298522B6 (en)
DE (4) DE122009000013I1 (en)
DK (1) DK1007505T3 (en)
ES (1) ES2197508T3 (en)
FR (1) FR09C0011I2 (en)
HU (1) HU225774B1 (en)
ID (1) ID23953A (en)
IL (2) IL134498A0 (en)
LU (2) LU91346I2 (en)
MY (1) MY127881A (en)
NL (1) NL300379I2 (en)
NO (2) NO326196B1 (en)
NZ (1) NZ502669A (en)
PE (1) PE108099A1 (en)
PL (1) PL194480B1 (en)
PT (1) PT1007505E (en)
RU (1) RU2186762C2 (en)
SI (1) SI1007505T1 (en)
SK (1) SK283773B6 (en)
TR (1) TR200000447T2 (en)
TW (1) TWI250142B (en)
WO (1) WO1999011605A1 (en)

Families Citing this family (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040072889A1 (en) * 1997-04-21 2004-04-15 Pharmacia Corporation Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia
CO4960662A1 (en) * 1997-08-28 2000-09-25 Novartis Ag CERTAIN 5-ALKYL-2-ARYLAMINOPHENYLACETIC ACIDS AND THEIR DERIVATIVES
EP1126841B1 (en) * 1998-11-02 2004-12-15 Merck & Co., Inc. Combinations of a 5ht1b/1d agonist and a selective cox-2 inhibitor for the treatment of migraine
US20040053900A1 (en) * 1998-12-23 2004-03-18 Pharmacia Corporation Method of using a COX-2 inhibitor and an aromatase inhibitor as a combination therapy
US20040122011A1 (en) * 1998-12-23 2004-06-24 Pharmacia Corporation Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy
GB9922830D0 (en) * 1999-09-27 1999-11-24 Novartis Ag Processes
CZ20013162A3 (en) 1999-12-08 2002-06-12 Pharmacia Corporation Preparations containing cyclooxygenase-2 inhibitor, exhibiting quick rise of therapeutic effect
AR030630A1 (en) * 2000-09-11 2003-08-27 Novartis Ag PHARMACEUTICAL COMPOSITIONS
AU2001216038A1 (en) * 2000-11-14 2002-05-27 Alcon Laboratories Inc. Treatment of glaucoma and ocular hypertension
US20050264906A1 (en) * 2004-05-25 2005-12-01 Haratsch Erich F Method and apparatus for reduced-state Viterbi detection in a read channel of a magnetic recording system
US7656959B2 (en) 2001-04-13 2010-02-02 Agere Systems Inc. Pipelined decision-feedback unit in a reduced-state viterbi detector with local feedback
DE10129320A1 (en) * 2001-06-19 2003-04-10 Norbert Mueller Use of cyclooxygenase-2 inhibitor in the preparation of a medicament for treating psychiatric disorders e.g. schizophrenia
US20060167074A1 (en) * 2001-06-19 2006-07-27 Norbert Muller Methods and compositions for the treatment of psychiatric disorders
AR038957A1 (en) 2001-08-15 2005-02-02 Pharmacia Corp COMBINATION THERAPY FOR CANCER TREATMENT
AR036312A1 (en) * 2001-08-31 2004-08-25 Novartis Ag PHARMACEUTICAL COMPOSITION
WO2003022815A1 (en) 2001-09-10 2003-03-20 Sugen, Inc. 3-(4,5,6,7-tetrahydroindol-2-ylmethylidiene)-2-indolinone derivatives as kinase inhibitors
US7288246B2 (en) * 2001-09-13 2007-10-30 The Board Of Regents Of The University Of Oklahoma Method of alleviating chronic pain via peripheral glutaminase regulation
US7504231B2 (en) * 2001-09-13 2009-03-17 The Board Of Regents Of The University Of Oklahoma Method of alleviating chronic pain via peripheral inhibition of neurotransmitter synthesis
GB0124459D0 (en) * 2001-10-11 2001-12-05 Novartis Ag Organic compounds
CN100506224C (en) * 2001-10-25 2009-07-01 诺瓦提斯公司 Combinations Containing Selective Cyclooxygenase-2 Inhibitors
ES2280597T3 (en) * 2001-11-06 2007-09-16 Novartis Ag CYCLLOXYGENASA-2 INHIBITOR COMBINATION / HISTONE DEACETILASE INHIBITOR.
US20030212138A1 (en) * 2002-01-14 2003-11-13 Pharmacia Corporation Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor
US20030220374A1 (en) * 2002-01-14 2003-11-27 Pharmacia Corporation Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors
GB0201520D0 (en) * 2002-01-23 2002-03-13 Novartis Ag Pharmaceutical uses
PL370907A1 (en) * 2002-03-07 2005-05-30 Novartis Ag Pharmaceutical compositions
GB0209257D0 (en) * 2002-04-23 2002-06-05 Novartis Ag Organic compounds
WO2003103602A2 (en) 2002-06-11 2003-12-18 Nitromed, Inc. Nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use
ITMI20021391A1 (en) 2002-06-25 2003-12-29 Nicox Sa NITRO-DERIVATIVES OF CYCLOOXYGENASE-2 INHIBITORS
CN101897662B (en) 2002-07-23 2013-05-22 诺瓦提斯公司 Ophtalmic ointment composition comprising a drug, an ointment base and a solubilizing/dispersing agent
UY27939A1 (en) 2002-08-21 2004-03-31 Glaxo Group Ltd COMPOUNDS
AU2003294221A1 (en) * 2002-09-13 2004-04-19 Kenneth E. Miller Method of alleviating pain via inhibition of neurotransmitter synthesis
GB0224198D0 (en) * 2002-10-17 2002-11-27 Novartis Ag Organic compounds
US7632866B2 (en) * 2002-10-21 2009-12-15 Ramot At Tel Aviv University Derivatives of N-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators
US20040147581A1 (en) * 2002-11-18 2004-07-29 Pharmacia Corporation Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy
PE20040844A1 (en) * 2002-11-26 2004-12-30 Novartis Ag PHENYLACETIC ACIDS AND DERIVATIVES AS COX-2 INHIBITORS
US20040204411A1 (en) * 2002-12-17 2004-10-14 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
BR0317384A (en) * 2002-12-18 2005-11-16 Novartis Ag Combinations of valsartan with cox-2 inhibitors
US7157577B2 (en) 2003-03-07 2007-01-02 Sugen Inc. 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors
TWI327913B (en) * 2003-03-12 2010-08-01 Novartis Ag Pharmaceutical composition comprising 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid
US20040220155A1 (en) * 2003-03-28 2004-11-04 Pharmacia Corporation Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith
SE0301010D0 (en) 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
US20040220187A1 (en) * 2003-04-22 2004-11-04 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a sodium ion channel blocker for the treatment of pain, inflammation or inflammation mediated disorders
WO2004093816A2 (en) * 2003-04-22 2004-11-04 Pharmacia Corporation Compositions comprising a selective cox-2 inhibitor and a calcium modulating agent
US20060135506A1 (en) * 2003-04-22 2006-06-22 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a calcium modulating agent for the treatment of pain, inflammation or inflammation mediated disorders
WO2004093895A1 (en) * 2003-04-22 2004-11-04 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a potassium ion channel modulator for the treatment of pain, inflammation or inflammation mediated disorders
WO2004098619A2 (en) 2003-05-07 2004-11-18 Osteologix A/S Treating cartilage / bone conditions with water-soluble strontium salts
US20050107387A1 (en) * 2003-05-13 2005-05-19 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a peroxisome proliferator activated receptor agonist for the treatment of ischemic mediated central nervous system disorders
WO2004103286A2 (en) * 2003-05-14 2004-12-02 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a cholimergic agent
US7220422B2 (en) * 2003-05-20 2007-05-22 Allergan, Inc. Methods and compositions for treating eye disorders
US20060160776A1 (en) * 2003-05-28 2006-07-20 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a cannabinoid agent for the treatment of central nervous system damage
US20050101597A1 (en) * 2003-07-10 2005-05-12 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitior and a non-NMDA glutamate modulator for the treatment of central nervous system damage
US20050014729A1 (en) * 2003-07-16 2005-01-20 Pharmacia Corporation Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith
WO2005009354A2 (en) * 2003-07-17 2005-02-03 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and an ikk inhibitor for the treatment of ischemic-mediated central nervous system disorders or injury
SA04250253B1 (en) 2003-08-21 2009-11-10 استرازينيكا ايه بي Substiuted phenoxacetic as pharmaceutced compunds for treating respiratory diseases such as asthma and copd
US20050119262A1 (en) * 2003-08-21 2005-06-02 Pharmacia Corporation Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent
US20050130971A1 (en) * 2003-08-22 2005-06-16 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and phosphodiesterase inhibitor for the treatment of ischemic mediated central nervous system disorders or injury
US20050113409A1 (en) * 2003-09-03 2005-05-26 Pharmacia Corporation Method for the prevention or treatment of pain, inflammation and inflammation-related disorders with a Cox-2 selective inhibitor in combination with a nitric oxide-donating agent and compositions therewith
BRPI0414956A (en) * 2003-10-03 2006-11-14 Pharmacia Corp compositions of a selective cyclooxygenase-2 inhibitor administered under hypothermic conditions for the treatment of ischemia-mediated central nervous system disorders or lesions
CA2541265A1 (en) * 2003-10-08 2005-04-28 Novartis Ag Pharmaceutical composition comprising 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid
JP2007510756A (en) * 2003-11-12 2007-04-26 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー Compositions of cyclooxygenase-2 selective inhibitors and neurotrophic factor modulators for treating central nervous system mediated disorders
CA2750725C (en) 2004-01-07 2014-10-21 Seikagaku Corporation Spacer derivative for hyaluronic acid and non-steroidal anti-inflammatory drug residues
BRPI0509184A (en) * 2004-03-23 2007-09-18 Novartis Ag pharmaceutical compositions
TW200603792A (en) * 2004-04-23 2006-02-01 Pharmacia & Upjohn Co Llc Monotherapy for the treatment of psoriasis with cyclooxygenase-2 selective inhibitors
US7653154B2 (en) * 2004-05-25 2010-01-26 Agere Systems Inc. Method and apparatus for precomputation and pipelined selection of intersymbol interference estimates in a reduced-state Viterbi detector
US7380199B2 (en) * 2004-05-25 2008-05-27 Agere Systems Inc. Method and apparatus for precomputation and pipelined selection of branch metrics in a reduced-state Viterbi detector
US7487432B2 (en) * 2004-05-25 2009-02-03 Agere Systems Inc. Method and apparatus for multiple step Viterbi detection with local feedback
GB0415320D0 (en) 2004-07-08 2004-08-11 Astrazeneca Ab Novel compounds
GB0416508D0 (en) * 2004-07-23 2004-08-25 Merck Sharp & Dohme Therapeutic agents
GB0418830D0 (en) 2004-08-24 2004-09-22 Astrazeneca Ab Novel compounds
DE102004044827A1 (en) * 2004-09-16 2006-03-23 Bayer Cropscience Ag Iodine-phenyl-substituted cyclic ketoenols
WO2006056752A1 (en) 2004-11-23 2006-06-01 Astrazeneca Ab Phenoxyacetic acid derivatives useful for treating respiratory diseases
UY29298A1 (en) 2004-12-23 2006-05-31 Glaxo Group Ltd COMPOUNDS
WO2006091571A2 (en) * 2005-02-22 2006-08-31 Merial Limited Methods for selectively treating cox-2 mediated disorders by administering gamma-tocopherol
KR101193797B1 (en) 2005-04-26 2012-10-23 화이자 인코포레이티드 P-cadherin antibodies
AU2006244393B2 (en) * 2005-05-05 2012-06-21 Cook Biotech Incorporated Implantable materials and methods for inhibiting tissue adhesion formation
HUE025608T2 (en) 2005-09-07 2016-03-29 Amgen Fremont Inc Human monoclonal antibodies to activin receptor-like kinase-1 (ALK-1)
JP5155171B2 (en) 2005-10-06 2013-02-27 アストラゼネカ・アクチエボラーグ New compounds
TW200745003A (en) 2005-10-06 2007-12-16 Astrazeneca Ab Novel compounds
JP2007275193A (en) * 2006-04-04 2007-10-25 Fujifilm Corp Optical probe and optical tomographic imaging apparatus
AR061623A1 (en) 2006-06-26 2008-09-10 Novartis Ag PHENYLACETIC ACID DERIVATIVES
GB0704407D0 (en) 2007-03-07 2007-04-18 Glaxo Group Ltd Compounds
UA100983C2 (en) 2007-07-05 2013-02-25 Астразенека Аб Biphenyloxypropanoic acid as crth2 modulator and intermediates
US7943658B2 (en) * 2007-07-23 2011-05-17 Bristol-Myers Squibb Company Indole indane amide compounds useful as CB2 agonists and method
EP2203411B1 (en) 2007-09-20 2016-01-06 Ramot at Tel-Aviv University Ltd. N-phenyl anthranilic acid derivatives and uses thereof
US20090082452A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched lumiracoxib
AU2009210446C1 (en) 2008-02-01 2013-01-10 Brickell Biotech, Inc. N,N-disubstituted aminoalkylbiphenyl antagonists of prostaglandin D2 receptors
WO2009102893A2 (en) 2008-02-14 2009-08-20 Amira Pharmaceuticals, Inc. CYCLIC DIARYL ETHER COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 receptors
WO2009108720A2 (en) 2008-02-25 2009-09-03 Amira Pharmaceuticals, Inc. Antagonists of prostaglandin d2 receptors
WO2009145989A2 (en) 2008-04-02 2009-12-03 Amira Pharmaceuticals, Inc. Aminoalkylphenyl antagonists of prostaglandin d2 receptors
WO2010003127A2 (en) * 2008-07-03 2010-01-07 Amira Pharmaceuticals, Inc. Antagonists of prostaglandin d2 receptors
GB0813144D0 (en) 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
GB0813142D0 (en) 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
GB2463788B (en) 2008-09-29 2010-12-15 Amira Pharmaceuticals Inc Heteroaryl antagonists of prostaglandin D2 receptors
US8378107B2 (en) 2008-10-01 2013-02-19 Panmira Pharmaceuticals, Llc Heteroaryl antagonists of prostaglandin D2 receptors
WO2010042652A2 (en) 2008-10-08 2010-04-15 Amira Pharmaceuticals, Inc. Heteroalkyl biphenyl antagonists of prostaglandin d2 receptors
EP2177215A1 (en) 2008-10-17 2010-04-21 Laboratorios Del. Dr. Esteve, S.A. Co-crystals of tramadol and NSAIDs
US8227451B2 (en) * 2008-11-12 2012-07-24 Auspex Pharmaceuticals Phenylacetic acid inhibitors of cyclooxygenase
WO2010057118A2 (en) 2008-11-17 2010-05-20 Amira Pharmaceuticals, Inc. Heterocyclic antagonists of prostaglandin d2 receptors
WO2011012622A1 (en) 2009-07-30 2011-02-03 Glaxo Group Limited Benzoxazinone derivatives for the treatment of glytl mediated disorders
KR20120038544A (en) 2009-07-31 2012-04-23 판미라 파마슈티칼스, 엘엘씨 Ophthalmic pharmaceutical compositions of dp2 receptor antagonists
KR20120047273A (en) 2009-08-05 2012-05-11 판미라 파마슈티칼스, 엘엘씨 Dp2 antagonist and uses thereof
WO2011023753A1 (en) 2009-08-27 2011-03-03 Glaxo Group Limited Benzoxazine derivatives as glycine transport inhibitors
SG182398A1 (en) 2010-01-06 2012-08-30 Panmira Pharmaceuticals Llc Dp2 antagonist and uses thereof
GB201000685D0 (en) 2010-01-15 2010-03-03 Glaxo Group Ltd Novel compounds
GB201007791D0 (en) 2010-05-10 2010-06-23 Glaxo Group Ltd Novel compounds
GB201007789D0 (en) 2010-05-10 2010-06-23 Glaxo Group Ltd Novel Compound
US9115132B2 (en) 2010-07-09 2015-08-25 Convergence Pharmaceuticals Limited Tetrazole compounds as calcium channel blockers
RU2439053C1 (en) * 2010-08-03 2012-01-10 Государственное образовательное учреждение высшего профессионального образования "Пермский государственный университет" Diarylamines and synthesis method thereof
US8892989B1 (en) * 2010-08-26 2014-11-18 Clearslide, Inc. Method for searching companies and people
US8900798B2 (en) 2010-10-18 2014-12-02 Eastman Kodak Company On-press developable lithographic printing plate precursors
US20120090486A1 (en) 2010-10-18 2012-04-19 Celin Savariar-Hauck Lithographic printing plate precursors and methods of use
US20120141941A1 (en) 2010-12-03 2012-06-07 Mathias Jarek Developing lithographic printing plate precursors in simple manner
US20120141935A1 (en) 2010-12-03 2012-06-07 Bernd Strehmel Developer and its use to prepare lithographic printing plates
US20120141942A1 (en) 2010-12-03 2012-06-07 Domenico Balbinot Method of preparing lithographic printing plates
US8933132B2 (en) 2011-01-19 2015-01-13 Convergence Pharmaceuticals Limited Tricyclic substituted benzenesulfonamide piperazine derivatives as CAV2.2 calcium channel blockers
US20120199028A1 (en) 2011-02-08 2012-08-09 Mathias Jarek Preparing lithographic printing plates
EA026702B1 (en) 2011-09-16 2017-05-31 Санофи Aniline derivatives, their preparation and their therapeutic application
US8632941B2 (en) 2011-09-22 2014-01-21 Eastman Kodak Company Negative-working lithographic printing plate precursors with IR dyes
US9029063B2 (en) 2011-09-22 2015-05-12 Eastman Kodak Company Negative-working lithographic printing plate precursors
CN102311355B (en) * 2011-09-26 2014-02-05 扬州天和药业有限公司 Preparation method of rofecoxib
GB201122113D0 (en) 2011-12-22 2012-02-01 Convergence Pharmaceuticals Novel compounds
US8679726B2 (en) 2012-05-29 2014-03-25 Eastman Kodak Company Negative-working lithographic printing plate precursors
US9063423B2 (en) 2013-02-28 2015-06-23 Eastman Kodak Company Lithographic printing plate precursors and use
US9201302B2 (en) 2013-10-03 2015-12-01 Eastman Kodak Company Negative-working lithographic printing plate precursor
GB201417499D0 (en) 2014-10-03 2014-11-19 Convergence Pharmaceuticals Novel use
GB201417497D0 (en) 2014-10-03 2014-11-19 Convergence Pharmaceuticals Novel use
GB201417500D0 (en) 2014-10-03 2014-11-19 Convergence Pharmaceuticals Novel use
JP7096598B2 (en) 2016-09-07 2022-07-06 トラスティーズ オブ タフツ カレッジ Combination therapy with immuno-DASH inhibitors and PGE2 antagonists
KR20200113036A (en) 2017-03-14 2020-10-05 세이가가쿠 고교 가부시키가이샤 Composition for treating joint diseases and kit including same
CA3051663A1 (en) 2017-03-14 2018-09-20 Seikagaku Corporation Composition for treating joint diseases and kit including same
KR102069205B1 (en) * 2017-08-09 2020-01-22 연성정밀화학(주) Process for Preparing Latanoprostene bunod and Intermediate Therefor
CN109694330B (en) * 2017-10-24 2023-10-20 乳源瑶族自治县东阳光生物科技有限公司 Preparation method of acid
WO2020021077A1 (en) 2018-07-27 2020-01-30 Krka, D.D., Novo Mesto A process for the preparation of polymorphic form of robenacoxib
CN109503399B (en) * 2018-12-29 2021-12-24 江苏天和制药有限公司 A kind of preparation method of robencoxib
CN110437090A (en) * 2019-07-31 2019-11-12 江苏天和制药有限公司 A kind of rofecoxib tripolymer and preparation method thereof
CN111807978B (en) * 2020-07-29 2023-03-14 武汉川泰科技有限公司 Preparation method of Robecoxib
US20240165148A1 (en) 2021-03-15 2024-05-23 Saul Yedgar Hyaluronic acid-conjugated dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (nsaids) for treating or alleviating inflammatory diseases
EP4281183A4 (en) 2022-03-23 2025-07-02 Alivira Animal Health Ltd IMPROVED PROCESS FOR THE PURIFICATION OF ROBENACOXIB

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3895063A (en) 1965-04-08 1975-07-15 Ciba Geigy Corp Substituted Anilino Benzyl Alcohols
US3558690A (en) 1965-04-08 1971-01-26 Gelgy Chemical Corp Substituted derivatives of 2-anilinophenylacetic acids and a process of preparation
GB1166861A (en) 1966-01-15 1969-10-15 Aspro Nicholas Ltd New Diphenylamine Derivatives and Compositions containing them
US3652762A (en) 1970-04-14 1972-03-28 Ciba Geigy Corp Pharmaceutical compositions and methods employing substituted derivatives of 2-anilinophenylacetic acids and esters
US4173577A (en) 1970-09-09 1979-11-06 Ciba-Geigy Corporation Phenylacetohydroxamic acids
ES520813A0 (en) 1983-03-21 1984-05-16 Prodes Sa PROCEDURE FOR OBTAINING THE ESTER OF ACID 2- (2,6-DICHLOROPHENYL) AMINO BENZENOACETIC WITH GLYCOLIC ACID.
DE3445011A1 (en) 1983-12-13 1985-06-13 Ciba-Geigy Ag, Basel Novel aniline derivative, process for its preparation, and its use
GR900100380A (en) * 1989-05-20 1991-10-10 Fisons Plc Method of preparation of anti-inflammatory derivatives of aminophenol.
IT1256345B (en) 1992-08-20 1995-12-01 NITRIC ESTERS OF PHENYLACETIC 2- (2,6-DI-HALO-PHENYLAMIN) DERIVATIVES AND PROCEDURE FOR THEIR PREPARATION
CZ380596A3 (en) 1994-06-29 1997-08-13 Ciba Geigy Ag Salts of 2-(2,6-dichlorophenyl)amino)phenylacetoxyacetic acid with cations of organic bases, process of their preparation, pharmaceutical compositions containing thereof and their use
JPH0977664A (en) 1995-09-13 1997-03-25 Yakult Honsha Co Ltd Cyclooxygenase-2 specific inhibitor and anti-inflammatory agent
CO4960662A1 (en) * 1997-08-28 2000-09-25 Novartis Ag CERTAIN 5-ALKYL-2-ARYLAMINOPHENYLACETIC ACIDS AND THEIR DERIVATIVES

Also Published As

Publication number Publication date
RU2186762C2 (en) 2002-08-10
AR015157A1 (en) 2001-04-18
BR9812010A (en) 2000-12-12
CN1268112A (en) 2000-09-27
PT1007505E (en) 2003-08-29
DE122009000013I1 (en) 2009-06-25
ATE237580T1 (en) 2003-05-15
IL134498A (en) 2009-06-15
SK283773B6 (en) 2004-01-08
NO2009007I2 (en) 2010-06-07
EP1007505A1 (en) 2000-06-14
KR20010023344A (en) 2001-03-26
TR200000447T2 (en) 2000-07-21
CA2298033A1 (en) 1999-03-11
US6727281B2 (en) 2004-04-27
KR100637296B1 (en) 2006-10-23
PL338357A1 (en) 2000-10-23
NO2009007I1 (en) 2009-04-06
US7115662B2 (en) 2006-10-03
PL194480B1 (en) 2007-06-29
US20040122254A1 (en) 2004-06-24
US6291523B1 (en) 2001-09-18
LU91540I2 (en) 2009-05-11
CY2007020I1 (en) 2012-01-25
CO4960662A1 (en) 2000-09-25
NO20000943D0 (en) 2000-02-25
AU9534098A (en) 1999-03-22
NL300379I2 (en) 2010-02-01
CN1140500C (en) 2004-03-03
DK1007505T3 (en) 2003-07-21
HU225774B1 (en) 2007-08-28
SK2472000A3 (en) 2000-09-12
DE122007000035I2 (en) 2010-07-01
NZ502669A (en) 2002-02-01
NO20000943L (en) 2000-02-25
WO1999011605A8 (en) 2000-03-02
EP1007505B1 (en) 2003-04-16
US6451858B2 (en) 2002-09-17
DE69813570T2 (en) 2004-02-12
CZ2000714A3 (en) 2000-06-14
WO1999011605A1 (en) 1999-03-11
HK1031374A1 (en) 2001-06-15
DE69813570D1 (en) 2003-05-22
ES2197508T3 (en) 2004-01-01
MY127881A (en) 2006-12-29
BR9812010B1 (en) 2010-12-14
HUP0002514A2 (en) 2000-12-28
AU743371B2 (en) 2002-01-24
CY2007020I2 (en) 2012-01-25
CZ298522B6 (en) 2007-10-24
US20020013369A1 (en) 2002-01-31
TWI250142B (en) 2006-03-01
FR09C0011I1 (en) 2009-04-17
JP2001514244A (en) 2001-09-11
DE122007000035I1 (en) 2007-07-19
NO326196B1 (en) 2008-10-13
US20020183391A1 (en) 2002-12-05
PE108099A1 (en) 1999-11-18
LU91346I2 (en) 2007-09-11
NL300379I1 (en) 2009-05-06
SI1007505T1 (en) 2003-10-31
US6310099B1 (en) 2001-10-30
IL134498A0 (en) 2001-04-30
ID23953A (en) 2000-06-08
HUP0002514A3 (en) 2002-11-28
JP3704470B2 (en) 2005-10-12
CA2298033C (en) 2007-10-02

Similar Documents

Publication Publication Date Title
BE2018C032I2 (en)
CH0944937H2 (en)
BE2013C047I2 (en)
BR9701757A (en)
BR9700653A (en)
IN183096B (en)
CN3056251S (en)
CN3056418S (en)
BY4349C1 (en)
CN3053170S (en)
CN3053500S (en)
CN3053525S (en)
CN3054099S (en)
CN3054162S (en)
CN3054556S (en)
CN3054902S (en)
CN3055123S (en)
CN3055179S (en)
CN3055389S (en)
CN3055471S (en)
CN3055519S (en)
CN3055603S (en)
CN3055713S (en)
CN3056209S (en)
CN3056875S (en)